Jennifer L Sherr

List of Publications by Year
in descending order

75 papers	3,477 citations	126907 33 h-index	144013 57 g-index
76 all docs	76 docs citations	76 times ranked	2726 citing authors

#	Article	IF	Citations
1	Effect of Continuous Glucose Monitoring on Glycemic Control in Adolescents and Young Adults With Type 1 Diabetes. JAMA - Journal of the American Medical Association, 2020, 323, 2388.	7.4	238
2	Use of insulin pump therapy in children and adolescents with type 1 diabetes and its impact on metabolic control: comparison of results from three large, transatlantic paediatric registries. Diabetologia, 2016, 59, 87-91.	6.3	203
3	Continuous glucose monitoring and glycemic control among youth with type 1 diabetes: International comparison from the T1D Exchange and DPV Initiative. Pediatric Diabetes, 2018, 19, 1271-1275.	2.9	186
4	ISPAD Clinical Practice Consensus Guidelines 2018: Diabetes technologies. Pediatric Diabetes, 2018, 19, 302-325.	2.9	170
5	American Association of Clinical Endocrinology Clinical Practice Guideline: The Use of Advanced Technology in the Management of Persons With Diabetes Mellitus. Endocrine Practice, 2021, 27, 505-537.	2.1	135
6	Multicenter Trial of a Tubeless, On-Body Automated Insulin Delivery System With Customizable Glycemic Targets in Pediatric and Adult Participants With Type 1 Diabetes. Diabetes Care, 2021, 44, 1630-1640.	8.6	133
7	Insulin dose optimization using an automated artificial intelligence-based decision support system in youths with type 1 diabetes. Nature Medicine, 2020, 26, 1380-1384.	30.7	127
8	Effect of Pramlintide on Prandial Glycemic Excursions During Closed-Loop Control in Adolescents and Young Adults With Type 1 Diabetes. Diabetes Care, 2012, 35, 1994-1999.	8.6	124
9	Continuous Glucose Monitoring Profiles in Healthy Nondiabetic Participants: A Multicenter Prospective Study. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 4356-4364.	3.6	118
10	Safety and Glycemic Outcomes During the MiniMedâ„¢ Advanced Hybrid Closed-Loop System Pivotal Trial in Adolescents and Adults with Type 1 Diabetes. Diabetes Technology and Therapeutics, 2022, 24, 178-189.	4.4	107
11	Reduced Hypoglycemia and Increased Time in Target Using Closed-Loop Insulin Delivery During Nights With or Without Antecedent Afternoon Exercise in Type 1 Diabetes. Diabetes Care, 2013, 36, 2909-2914.	8.6	105
12	Optimizing Hybrid Closed-Loop Therapy in Adolescents and Emerging Adults Using the MiniMed 670G System. Diabetes Care, 2018, 41, 789-796.	8.6	101
13	Glucagon Nasal Powder: A Promising Alternative to Intramuscular Glucagon in Youth With Type 1 Diabetes. Diabetes Care, 2016, 39, 555-562.	8.6	91
14	Intranasal Glucagon for Treatment of Insulin-Induced Hypoglycemia in Adults With Type 1 Diabetes: A Randomized Crossover Noninferiority Study. Diabetes Care, 2016, 39, 264-270.	8.6	86
15	Effect of Insulin Feedback on Closed-Loop Glucose Control: A Crossover Study. Journal of Diabetes Science and Technology, 2012, 6, 1123-1130.	2.2	85
16	Mitigating Meal-Related Glycemic Excursions in an Insulin-Sparing Manner During Closed-Loop Insulin Delivery: The Beneficial Effects of Adjunctive Pramlintide and Liraglutide. Diabetes Care, 2016, 39, 1127-1134.	8.6	75
17	High residual C-peptide likely contributes to glycemic control in type 1 diabetes. Journal of Clinical Investigation, 2020, 130, 1850-1862.	8.2	73
18	A Glycemia Risk Index (GRI) of Hypoglycemia and Hyperglycemia for Continuous Glucose Monitoring Validated by Clinician Ratings. Journal of Diabetes Science and Technology, 2023, 17, 1226-1242.	2.2	69

#	Article	IF	Citations
19	Safety and Performance of the Omnipod Hybrid Closed-Loop System in Adults, Adolescents, and Children with Type 1 Diabetes Over 5 Days Under Free-Living Conditions. Diabetes Technology and Therapeutics, 2020, 22, 174-184.	4.4	61
20	Longitudinal Changes in Continuous Glucose Monitoring Use Among Individuals With Type 1 Diabetes: International Comparison in the German and Austrian DPV and U.S. T1D Exchange Registries. Diabetes Care, 2020, 43, e1-e2.	8.6	59
21	Skin and Adhesive Issues With Continuous Glucose Monitors. Journal of Diabetes Science and Technology, 2014, 8, 745-751.	2.2	57
22	Acute Metabolic Effects of Exenatide in Patients With Type 1 Diabetes With and Without Residual Insulin to Oral and Intravenous Glucose Challenges. Diabetes Care, 2014, 37, 210-216.	8.6	56
23	Blunted glucagon but not epinephrine responses to hypoglycemia occurs in youth with less than 1 yr duration of type 1 diabetes mellitus. Pediatric Diabetes, 2014, 15, 127-134.	2.9	49
24	Automated hybrid closed-loop control with a proportional-integral-derivative based system in adolescents and adults with type 1 diabetes: individualizing settings for optimal performance. Pediatric Diabetes, 2017, 18, 348-355.	2.9	46
25	New-generation diabetes management: glucose sensor-augmented insulin pump therapy. Expert Review of Medical Devices, 2011, 8, 449-458.	2.8	45
26	Type 1 diabetes glycemic management: Insulin therapy, glucose monitoring, and automation. Science, 2021, 373, 522-527.	12.6	43
27	Schooling diabetes: Use of continuous glucose monitoring and remote monitors in the home and school settings. Pediatric Diabetes, 2018, 19, 92-97.	2.9	42
28	Prevention of type 1 diabetes: the time has come. Nature Clinical Practice Endocrinology and Metabolism, 2008, 4, 334-343.	2.8	41
29	Evolution of Abnormal Plasma Glucagon Responses to Mixed-Meal Feedings in Youth With Type 1 Diabetes During the First 2 Years After Diagnosis. Diabetes Care, 2014, 37, 1741-1744.	8.6	38
30	Efficacy and Safety of Mini-Dose Glucagon for Treatment of Nonsevere Hypoglycemia in Adults With Type 1 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 2994-3001.	3.6	38
31	Past, present, and future of insulin pump therapy: better shot at diabetes control. Mount Sinai Journal of Medicine, 2008, 75, 352-361.	1.9	37
32	Connecting the Dots: Validation of Time in Range Metrics With Microvascular Outcomes. Diabetes Care, 2019, 42, 345-348.	8.6	36
33	Gender differences in diabetes self-care in adults with type 1 diabetes: Findings from the T1D Exchange clinic registry. Journal of Diabetes and Its Complications, 2018, 32, 961-965.	2.3	35
34	Safety of Nighttime 2-Hour Suspension of Basal Insulin in Pump-Treated Type 1 Diabetes Even in the Absence of Low Glucose. Diabetes Care, 2014, 37, 773-779.	8.6	34
35	The Alteration of Aspart Insulin Pharmacodynamics When Mixed With Detemir Insulin. Diabetes Care, 2012, 35, 690-692.	8.6	33
36	Lack of Association Between Residual Insulin Production and Glucagon Response to Hypoglycemia in Youth With Short Duration of Type 1 Diabetes. Diabetes Care, 2013, 36, 1470-1476.	8.6	32

#	Article	IF	Citations
37	Mitigating Reductions in Glucose During Exercise on Closed-Loop Insulin Delivery: The Ex-Snacks Study. Diabetes Technology and Therapeutics, 2016, 18, 794-799.	4.4	32
38	Safety and Glycemic Outcomes With a Tubeless Automated Insulin Delivery System in Very Young Children With Type 1 Diabetes: A Single-Arm Multicenter Clinical Trial. Diabetes Care, 2022, 45, 1907-1910.	8.6	28
39	Faster In and Faster Out: Accelerating Insulin Absorption and Action by Insulin Infusion Site Warming. Diabetes Technology and Therapeutics, 2014, 16, 20-25.	4.4	27
40	Risk Factors for Cardiovascular Disease (CVD) in Adults with Type 1 Diabetes: Findings from Prospective Real-life T1D Exchange Registry. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e2032-e2038.	3.6	26
41	Altered Patterns of Early Metabolic Decompensation in Type 1 Diabetes During Treatment with a SGLT2 Inhibitor: An Insulin Pump Suspension Study. Diabetes Technology and Therapeutics, 2017, 19, 618-622.	4.4	24
42	The dawn of automated insulin delivery: A new clinical framework to conceptualize insulin administration. Pediatric Diabetes, 2018, 19, 14-17.	2.9	23
43	Achievement of Target A1C Levels With Negligible Hypoglycemia and Low Glucose Variability in Youth With Short-Term Type 1 Diabetes and Residual Â-Cell Function. Diabetes Care, 2012, 35, 817-820.	8.6	22
44	Accuracy of a Fourth-Generation Continuous Glucose Monitoring System in Children and Adolescents with Type 1 Diabetes. Diabetes Technology and Therapeutics, 2018, 20, 576-584.	4.4	22
45	Glucagon Administration by Nasal and Intramuscular Routes in Adults With Type 1 Diabetes During Insulin-Induced Hypoglycaemia: A Randomised, Open-Label, Crossover Study. Diabetes Therapy, 2020, 11, 1591-1603.	2.5	21
46	Characterization of residual Î² cell function in longâ€standing type 1 diabetes. Diabetes/Metabolism Research and Reviews, 2014, 30, 154-162.	4.0	20
47	Acceleration of insulin pharmacodynamic profile by a novel insulin infusion site warming device. Pediatric Diabetes, 2012, 14, n/a-n/a.	2.9	19
48	Pramlintide but Not Liraglutide Suppresses Meal-Stimulated Glucagon Responses in Type 1 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 1088-1094.	3.6	19
49	Effect of Exercise and Meals on Continuous Glucose Monitor Data in Healthy Individuals Without Diabetes. Journal of Diabetes Science and Technology, 2021, 15, 593-599.	2.2	19
50	Closing the Loop on Managing Youth With Type 1 Diabetes: Children Are Not Just Small Adults. Diabetes Care, 2018, 41, 1572-1578.	8.6	18
51	Continuous Ketone Monitoring Consensus Report 2021. Journal of Diabetes Science and Technology, 2022, 16, 689-715.	2.2	18
52	How introduction of automated insulin delivery systems may influence psychosocial outcomes in adults with type 1 diabetes: Findings from the first investigation with the OmnipodÂ® 5 System. Diabetes Research and Clinical Practice, 2022, 190, 109998.	2.8	15
53	Response to Comment on Rickels et al. Intranasal Glucagon for Treatment of Insulin-Induced Hypoglycemia in Adults With Type 1 Diabetes: A Randomized Crossover Noninferiority Study. Diabetes Care 2016;39:264â€“270. Diabetes Care, 2016, 39, e193-e194.	8.6	13
54	Pharmacologic treatment options for type 1 diabetes: whatâ€™s new?. Expert Review of Clinical Pharmacology, 2019, 12, 471-479.	3.1	13

#	Article	IF	Citations
55	Continuous glucose monitoring use and glucose variability in very young children with type 1 diabetes (<scp>VibRate</scp>): A multinational prospective observational <scp>realâ€world</scp> cohort study. Diabetes, Obesity and Metabolism, 2022, 24, 564-569.	4.4	12
56	From pumps to prevention: recent advances in the treatment of type 1 diabetes. Drug Discovery Today, 2009, 14, 973-981.	6.4	10
57	Clinical Implementation of the Omnipod 5 Automated Insulin Delivery System: Key Considerations for Training and Onboarding People With Diabetes. Clinical Diabetes, 2022, 40, 168-184.	2.2	10
58	No Summer Vacation From Diabetes: Glycemic Control in Pediatric Participants in the T1D Exchange Registry Based on Time of Year. Diabetes Care, 2016, 39, e214-e215.	8.6	9
59	Changes in Device Uptake and Glycemic Control among Pregnant Women With Type 1 Diabetes: Data From the T1D Exchange. Journal of Diabetes Science and Technology, 2020, 15, 193229682097212.	2.2	8
60	Hemoglobin A1c Patterns of Youth With Type 1 Diabetes 10 Years Post Diagnosis From 3 Continents. Pediatrics, 2021, 148, .	2.1	8
61	A Bridge to Insulin Pump Therapy: Twice-Daily Regimen with NPH and Detemir Insulins During Initial Treatment of Youth with Type 1 Diabetes Mellitus. Endocrine Practice, 2011, 17, 862-866.	2.1	6
62	Clinical equipoise: an argument for expedited approval of the first small step toward an autonomous artificial pancreas. Expert Review of Medical Devices, 2012, 9, 315-317.	2.8	5
63	A Pilot Study of Youth With Type 1 Diabetes Initiating Use of a Hybrid Closed-Loop System While Receiving a Behavioral Economics Intervention. Endocrine Practice, 2021, 27, 545-551.	2.1	5
64	Moving beyond subcutaneous insulin: the application of adjunctive therapies to the treatment of type 1 diabetes. Expert Opinion on Drug Delivery, 2017, 14, 1113-1131.	5.0	4
65	A Technological Revolution: The Integration of New Treatments to Manage Type 1 Diabetes. Pediatric Annals, 2019, 48, e311-e318.	0.8	4
66	Reversal of Ketosis in Type 1 Diabetes Is Not Adversely Affected by SGLT2 Inhibitor Therapy. Diabetes Technology and Therapeutics, 2019, 21, 101-104.	4.4	3
67	Diabetes Technology Meeting 2021. Journal of Diabetes Science and Technology, 2022, , 193229682210902.	2.2	2
68	Enlarging the loop: closed-loop insulin delivery for type 1 diabetes. Lancet, The, 2018, 392, 1282-1284.	13.7	1
69	Incident diabetes complications among women with type 1 diabetes based on parity. Journal of Maternal-Fetal and Neonatal Medicine, 2022, 35, 4629-4634.	1.5	1
70	Diabetes Technology Meeting 2020. Journal of Diabetes Science and Technology, 2021, 15, 916-960.	2.2	1
71	Diabetes Types 1 and 2 in the Pediatric Population. Pediatric Annals, 2012, 41, e1-7.	0.8	0
72	Insulin pumps in children with T1DMâ€"we told you so. Nature Reviews Endocrinology, 2013, 9, 629-630.	9.6	0

#	Article	IF	Citations
73	The dawn of automated insulin delivery: from promise to product. , 2020, , 327-356.		0
74	Adjunctive Therapies for Type 1 Diabetes. Contemporary Endocrinology, 2021, , 143-150.	0.1	0
75	Pharmacodynamics, pharmacokinetics, safety, and tolerability of a readyâ€toâ€use, room temperature, liquid stable glucagon administered via an autoinjector pen to youth with type 1 diabetes. Pediatric Diabetes, 2022, 23, 754-762.	2.9	0